Introduction
It has been gratifying in recent years to find research into vascular dementia increasing. It has always been the poor relation of stroke, transient ischaemic attack and amaurosis fugax in terms of research, rating alongside anterior ischaemic optic neuropathy in terms of neglect. Vascular dementia is a major public health problem which will increase with the aging of the population over the next 20 years. Community-based surveys have indicated that around 5% of people over the age of 65 and 15-20% of those over the age of 80 will suffer from severe dementia, with up to 40% of these being vascular in origin. 1 A number of community-based studies have related hypertension with cognitive decline 2 and dementia, 3, 4 although this has not been a universal finding, [5] [6] [7] perhaps related to blood pressure (BP) falling with the onset of dementia. 4 Recent clinical trials have examined whether the treatment of isolated systolic hypertension can reduce the incidence of dementia, vascular or otherwise. The results of the Systolic Hypertension in Europe Trial (Syst-Eur) suggested that the calcium channel blocker nitrendipine, with or without supplementary enalapril or hydrochlorothiazide, was capable of reducing the incidence of dementia over 2 years by 50%. 8 The incidence of Alzheimer's disease was also reduced in this study. This is in contrast with the findings of the Systolic Hypertension in the Elderly Programme (SHEP) in which treatment with chlorthalidone with or without supplementary atenolol failed to influence the incidence of dementia over 4.5 years. 9 Can we rely on the findings of the Syst-Eur Trial and how does this compare with previous work? What are the implications for future research and patient management?
Syst-Eur Trial methodology
The Systolic Hypertension in Europe Trial years with a systolic BP of between 160 to 219 mm Hg and a diastolic BP of below 95 mm Hg. They were randomised to nitrendipine 10 mg to 40 mg daily with the possible addition of enalapril 5 mg to 20 mg daily, hydrochlorothiazide 12.5 mg to 25 mg daily, or both. The aim was to reduce the systolic BP by at least 20 mm Hg to reach a value of below 150 mm Hg. Mini-mental state examination was performed annually and if 23 or less, formal psychometric testing assessed the patients to decide whether they fulfilled DSM-III-R criteria for dementia. The diagnosis of vascular dementia or Alzheimer's Disease was made using brain imaging and the Hachinski score.
Using the intention-to-treat analysis, after a median follow-up of 2 years, the incidence of dementia in the placebo group (n = 1180) was 7.7 cases per 1000 patient-years, compared with the active treatment arm (n = 1238) with an incidence of 3.8 cases per 1000 patient-years. This represented a 50% reduction in the rate of dementia on active treatment with 95% confidence intervals for this reduction ranging from between 0% and 76%. The level of significance is quoted as 'P = 0.05'. The trial was stopped prematurely because the second of four planned interim analyses showed a significant reduction in stroke which was the primary outcome measure of the study.
The statistical analysis and conduct of this trial can be criticised on a number of counts. As the authors themselves concede in the Discussion, the incidence of dementia in the control group of 7.5 per 1000 patient-years is low compared with the findings from population-based studies with an incidence of around 10 per 1000 patient-years. It is conceivable that, whatever the reason for this reduced incidence in the placebo group, it had a more profound effect on the active treatment group and therefore led to the apparent reduction in dementia incidence between the groups.
The actual difference of 21 cases of dementia in the placebo group compared to 11 in the active treatment group reached a significance value of exactly 0.05. Thus, the lower confidence interval for the difference between the groups was 0%. This raises concerns that there was no real difference between the two groups. The authors have also not been consistent since the a priori power calculation for the dementia part of this trial used a P value of 0.01 to assess significance not 0.05. The difference between the two arms would clearly not be significant at the 0.01 level.
Adding these points together with the premature termination of the study at just 2 years, with only two post-baseline assessments of cognition, we must conclude that the authors' assertion that this antihypertensive regime can reduce the incidence of dementia is premature.
Comparison with previous work
In the Systolic Hypertension in the Elderly Programme (SHEP), 4736 patients with systolic BP of 160 to 219 mm Hg and diastolic BP of less than 90 mm Hg were randomised to chlorthalidone (12.5-25 mg daily), with supplementary atenolol (25-50 mg daily) if necessary, or matching placebo. 9 After a mean follow-up period of 4.5 years, the incidence of dementia in the active treatment group was 1.6% which was not significantly different from the incidence of 1.9% in the placebo group. Like the SystEur Trial, SHEP demonstrated a significant reduction in the incidence of stroke with the treatment of systolic hypertension (absolute 5 year benefit of 30 events per 1000 participants) along with a reduction in non-fatal myocardial infarction and coronary death (absolute 5 year benefit of 55 events per 1000 participants).
The 1992 Cochrane systematic review examining randomised control trials comparing the calcium channel blocker nimodipine with placebo concluded that there was insufficient evidence to prove or disprove any effect of this agent on reducing the incidence of dementia. 10 In an open label, non-controlled trial of 17 patients with multi-infarct or mixed dementia, reducing systolic hypertension to within normal limits (135-150 mm Hg) improved cognition as measured with the Cognitive Capacity Screening Examination. 11 Interestingly, reducing BP below this level resulted in a deterioration of cognition.
Implications
Only two large-scale randomised controlled trials have examined the strategy of treating isolated systolic hypertension to reduce dementia (Syst-Eur 8 and SHEP 9 ). At present, no clear conclusions emerge from these studies. Further trials would be required to resolve this question. However, it is unlikely that such work will be performed on ethical grounds.
Both of the recent trials conclusively showed that reducing isolated systolic hypertension significantly reduces the incidence of stroke and cardiac morbidity and mortality. 8, 9 Therefore, it is unlikely that any medical ethics committee would countenance such a trial with a control arm comprised of no treatment.
What practical advice can be given to the clinician in this situation? Faced with a patient with isolated systolic hypertension, this should be treated to reduce the risk of stroke and serious cardiovascular events. It may reduce the likelihood of vascular dementia and even Alzheimer's disease. The patient presenting with a dementia, of whatever type, along with systolic hypertension should also have the latter reduced to within normal limits in the hope that this will prevent or reduce further cognitive decline.
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